Annual report 2009-2010 - Cancer Research Society

Annual report 2009-2010
Research leaves its mark
www.CancerResearchSociety.ca
Mission
Founded in 1945, the Cancer Research Society (CRS) is a national not-for-profit organization
whose sole mission is to fund cancer research exclusively and to offer seed money to the most
promising original ideas, projects and researchers across Canada.
Vision
For 65 years, the CRS has worked tirelessly toward one goal and one hope: defeating cancer.
History of the Cancer
Research Society
The CRS is the first Canadian organization whose sole purpose is to fund cancer research.
Since its founding in 1945, it has been helping Canadian researchers and physicians
to better understand the causes of cancer. The CRS contributes to the development of
effective treatments that improve patients’ quality of life and helps to protect Canadians’
health through cancer prevention.
For more than six decades, the CRS has continued to fulfill its mission by awarding
research grants and fellowships, and funding strategic scientific initiatives across Canada.
Table of contents
Mission - Vision - History............................................................................................... 2
Table of contents............................................................................................................. 3
Message from the President of the Board of Directors .................................................... 4
Message from the Executive Director.............................................................................. 5
Research and development
Key facts about cancer............................................................................................. 6
A look at some of our Canadian researchers........................................................7 - 8
Environment-Cancer Fundtm.................................................................................. 9
Fundraising activities..............................................................................................10 - 11
Financial activities..................................................................................................12 - 13
Board of Directors......................................................................................................... 14
Scientific partners.......................................................................................................... 14
Donors.......................................................................................................................... 15
Message from the President
of the Board of Directors
Our mission: funding the most
innovative and promising projects
When considering cancer, we can never adequately convey the fundamental role of research in
the fight against the over 200 types of this insidious disease that has the ability to mutate, adapt
and evolve over time. Investing in the most promising research projects is therefore critical,
and a stepping stone towards important progress: each day, we are learning more about how
cancer develops.
This perspective underlies the decision of the Cancer Research Society (CRS) to work with
its partners in order to primarily grant start-up funds to innovative projects. In 20092010, for example, a total of over $5.6 million was allocated to Canadian researchers.
Their work has culminated (and will continue to do so) in the discovery of novel concepts
that can lead to new means of treating, stopping the growth of, and even curing certain
types of cancers.
It is particularly interesting to note that the quality of the funding applications we receive has
risen over the past few years, with Canadian researchers putting forth original and scientifically
sound ideas: in the last year alone, nearly 40% of the applications submitted would have been
eligible for funding. This being said, the difficult economic situation that prevailed over the
past year limited us to funding only 28, or 36%, of all scientifically eligible applications. These
numbers are far too low. We must make even greater efforts to support the critical projects of our
talented researchers.
Striving to stay ahead of the game:
research in the field of environment-cancer
In an initiative to break new ground in the fight against cancer, the CRS created the
Environment-Cancer FundTM in 2006. According to an article published in Pharmaceutical
Research (volume 25, number 9, 2097-2116), it is believed that environmental causes could
be responsible for up to 90% of all cancers. It is thus imperative that our efforts include a focus
on this field of research: from 2006 to 2009, we honoured our commitments in this regard
by funding a total of three environment-cancer projects. Moreover, four new projects have
been announced for the coming year. The last fiscal year also saw the official announcement
of a major partnership with the Québec government in the field of environment-cancer, an
initiative that we hope will be replicated elsewhere in Canada. At the same time, the work
carried out by Dr. Jack Siemiatycki’s team, of the Guzzo Environment-Cancer Research
Chair of the Cancer Research Society in partnership with the Université de Montréal,
was particularly impressive this year: thus far, seven articles have been published and the
team participated in seven different conferences. I would specifically like to emphasize the
group’s research in the area of lung cancer and the environment, as well as its findings on
the effects of alcohol consumption on cancer. The scientific breakthroughs emanating from
this research are promising. They encourage us to continue our work in this field dedicated
to better understanding the detrimental effects of certain environments and lifestyle habits
on our health.
Thanks to the innovative projects carried out by our researchers and the ongoing support of
our partners and donors, the CRS can continue its mission and its funding of research. All
this is with a single goal in mind: defeating cancer!
Mario Chevrette, PhD
4
Cancer Research Society • Annual report 2009-2010
Message from
the Executive Director
Encouraging financial results that hold promise for the future
The Cancer Research Society’s 2009-2010 annual report gives me the occasion to make a positive
assessment of the fiscal year that has just ended. It is an opportune moment to underscore the
exceptional efforts of all the employees and volunteers of the Cancer Research Society (CRS) and
to extend our thanks to our donors for their generous support.
In addition to these encouraging results, it bears noting that the CRS is today reaping the
rewards of having opted for a prudent approach and sound strategies in response to the
economic challenges of the last few years. The guidelines we established last year focused on
general cost reductions, tighter administrative controls, and the development of more efficient
and profitable internal policies with regard to fundraising. Certain revenue diversification
initiatives, notably the creation of the CRS Challenge and the redesign of our website to
facilitate online contributions by donors, generated tangible results.
All of these measures allowed the CRS to maintain high standards in the area of sound
management, as well as to deliver encouraging financial results that hold promise for the future.
A vision for the long term
CRS is able to plan its cancer research funding over the long term because it has been
honing its expertise in this regard since the organization was founded in 1945. The CRS
was established 65 years ago, when it undertook its mission of exclusively funding scientific
research projects to support the fight against cancer. We are optimistic as we celebrate our
organization’s 65th anniversary this year. Firmly focused on the future, the CRS has every
right to be proud of its history of achievements.
Such a long tenure would not have been possible without the benevolent support of our
donors, the innovative projects carried out by our researchers, and the dedication of our
numerous partners and volunteers. We have endeavoured to diversify our partnerships through
the signing of new cause-related marketing agreements, the creation of targeted funds, and the
development of institutional alliances that have enabled us to expand our financial portfolio of
research funds to encompass various types of cancer.
One of our core initiatives in 2009-2010 was the update of the CRS website. This time- and
energy-intensive project resulted in the development of a tool that now makes it possible to
meet several critical scientific research and fundraising requirements: in addition to accepting
online donations, our new website also allows us to continually enhance our virtual portal of
fundraising activities and cancer research information and reference tools.
Upcoming challenges
In closing, I would like to once again mention our mission as well as the challenges we will soon
be facing. The Statistics Canada report on cancer survival rates published this year indicates
an overall upward trend across the country. This encouraging information is due, among
other things, to the role of research in enabling the development of increasingly personalized
medicine and therapy that is better targeted to the individual. While positive overall, the report
nonetheless illustrates the limited scientific progress made for certain types of cancers, these
often being the ones which are less funded and hence the focus of fewer research initiatives. For
this reason, we are more determined than ever to pursue our efforts vis-à-vis cancer research.
Statistics Canada estimates the new cancer cases in Canada in 2010 at approximately 173,800,
and posits that one out of every four Canadians will die from cancer. We are obviously far from
having beaten this disease. The challenges that await our researchers are significant, and their
mission critical.
Let us join together to help our researchers find a cure!
Andy Chabot
Cancer Research Society • Annual report 2009-2010
5
Faits saillants
RESEARCH
DEVELOPMENT
le cancer :
&
Key facts about cancer:
figures that give us hope
Statistics Canada estimates that in 2010, there will be an average of 20 new instances of
cancer and 8 cancer-related deaths in Canada each hour of each day, or 173,800 new cancer
cases and 76,200 deaths for the year as a whole. This predicted rise in the number of cancer
diagnoses is mostly due to demographic growth and the aging of the population.
This being said...
• The overall cancer rate among men over the age of 69 is dropping, primarily because of a
decrease in new lung cancer cases, a phenomenon associated to dwindling tobacco use among
the general population. Lung cancer, however, remains the leading cause of death for both men
and women.
• The mortality rate is nonetheless dropping among men in most age groups, as well as among
women under the age of 70.
• If we exclude lung cancer, the overall mortality rate due to cancer among women has dropped
by nearly 20% since 1981.
• While over half of the new cases of breast cancer occur in women between the ages of 50 and
60, there will be more deaths from breast cancer among women aged 80 or more. This is an
indication that screening and therapy are enabling middle-aged women to live longer.
• Most cases of prostate cancer will occur in men between the ages of 60 and 69. This being said,
deaths due to prostate cancer are more numerous among men aged 80 or more. These figures
presumably attest to the benefits of screening for men in their sixties as well as to the disease’s
slow progression in a large number of cases.
• Statistics Canada has published comparative data on cancer survival rates for persons diagnosed
between 1992 and 1994 and those diagnosed between 2004 and 2006. There is good news:
study results indicate that cancer survival rates have continued to rise in Canada, with the
report illustrating that “the five-year relative survival ratio is 62% for all types of cancers
combined.” These encouraging data are due, among other things, to the role played by research
in enabling the development of increasingly personalized medicine and treatment that is
better targeted to the individual.
6
Cancer Research Society • Annual report 2009-2010
Some of the year’s
notable projects
Basic research:
This year, the Cancer Research Society (CRS), in association with its partners, funded a total
of 88 research projects.
A look at some of our
Canadian researchers...
1.
The majority of cancer deaths are due to tumour metastasis, which occurs when
cancer cells break off from a primary tumour, enter the bloodstream and move
on to invade new tissue, where they form secondary or metastatic tumours. A
secondary tumour that develops in a critical organ such as the lungs can disrupt
vital functions and eventually cause death.
This year, the CRS has awarded grants to 9 research projects studying
metastatic tumours. One of these projects, led by Dr. Michael Gold in
British Columbia, is seeking to discover why cancer cells have an easier time
penetrating blood vessels when white blood cells are present. Because the
latter are more prevalent when there is inflammation, Dr. Gold is seeking to
determine whether such inflammation contributes to an increase in tumour
metastasis and if so, how anti-inflammatory drugs could prove effective in
fighting metastasis.
2.
In 2010, it is estimated that 4,000 Canadians will be diagnosed with pancreatic
cancer and that 3,900 will die from the disease. The survival rate for pancreatic
cancer, at a mere 6% five years after the initial diagnosis, ranks among the lowest
cancer survival rates, primarily because of the lack of effective treatment.
The CRS is currently funding 3 projects to study pancreatic cancer, including
an initiative spearheaded by Dr. Norman Kneteman of the University
of Alberta. Through his research, Dr. Kneteman is attempting to increase
pancreatic cancer cells’ sensitivity to the TRAIL anti-cancer molecule.
The increased sensitivity of cancer cells will be achieved by changing the
expression of certain genes such as cFLIP and RIP. This study could lead
to novel therapeutic approaches for more effectively fighting pancreatic
cancer and increasing patient survival rates.
Research leaves its mark
Cancer Research Society • Annual report 2009-2010
7
A look at some of our
Canadian researchers... continued
3.
There are genes, called tumour suppressors, whose role is to battle the development
of tumours. In the event of a mutation which has the effect of disabling a tumour
suppressor gene, the latter’s protective effect will disappear and tumours will develop.
The CRS is currently funding 6 projects to study tumour suppressor genes,
among these a study by Dr. Michael Mowat of the Manitoba Institute
of Cell Biology at the University of Manitoba. Dr. Mowat is using a mouse
model where the DIc tumour suppressor gene is deleted from various
tissues or organs in order to determine whether its absence leads to the
formation of more aggressive tumours. This mouse model will essentially
reproduce the process that occurs in cancer patients.
4.
Leukemia is one of the 9 most frequently diagnosed cancers in Canada, and it is
estimated that around 4,800 new cases will be identified in 2010. The leukemia
survival rate, 5 years after a diagnosis has been made, is 55%.
This year, the CRS has awarded grants to 4 research projects to study
leukemia. One of these projects is spearheaded by Dr. Reginald Gorczynski
of Toronto Hospital, who is studying the relationship between the expression
of CD200, the immunosuppressant protein found in the serum of patients
with chronic lymphocytic leukemia, and resistance to therapy. Through his
research, Dr. Gorczynski hopes to find a method of blocking the action of the
CD200 protein to improve leukemia therapy.
5.
Severe weight loss, called cachexia, is often observed in persons with various types of
cancer, and is a prognostic indicator at all stages of the disease. Cachexia frequently
leads to rapid progression of the cancer and is frequently associated with severe
malaise, fatigue and anorexia.
This year, the CRS is funding three projects on cancer cachexia, including
one led by Dr. Robert Sladek of Montréal’s McGill University. Dr. Sladek’s
research focuses on the proteins that cause the metabolic changes in the
liver that result in cancer cachexia. By helping us to better understand and
prevent cachexia, this study aims to slow down the growth of cancer.
8
Cancer Research Society • Annual report 2009-2010
Environment-Cancer FundTM
In 2008, thanks to the Environment-Cancer FundTM, the CRS launched a large-scale
project: the Guzzo Environment-Cancer Research Chair of the Cancer Research Society in
partnership with the Université de Montréal. This project’s research potential is immense,
covering the study of various types of cancer as well as a practically unlimited number of
substances to which humans are exposed throughout their lives.
The holder of the Environment-Cancer Chair, Dr. Jack Siemiatycki, leads
a team of colleagues, research assistants and graduate students from the
Centre de recherche du Centre hospitalier de l’Université de Montréal. They
are currently working on the project, “Determining the cancer risks associated
with different aspects of our environment.”
The team will also be attempting to determine whether excessive alcohol
consumption is associated with a higher risk of developing certain types of
cancer, such as oesophageal, liver, stomach, colon and prostate cancer.
They are also studying women’s hormonal characteristics, to identify whether
they can have an impact on the risk of developing lung cancer. The team will
also be investigating whether exposure to low levels of asbestos increases the
risk of lung cancer and mesothelioma, and is seeking to determine whether
women living near asbestos mines are at greater risk. Lastly, the team will
study the risks to workers who come into contact with paint and diesel fumes,
as well as those exposed to metals such as cadmium, nickel and chromium.
Allocation of funds invested in research for 2009-2010:
63%
Basic research
19%
Research alliance
program
10%
Environment-cancer
6%
Grants for strategic programs
2%
Fellowships
Cancer Research Society • Annual report 2009-2010
9
Fundraising activities
Each donation counts in our fight against cancer!
The Cancer Research Society (CRS) collects public donations as part of its activities as a
charitable organization. This year, hundreds of thousands of donors responded to our appeal
by generously supporting the Society’s mission. Each donation we receive takes us one step
further in our fight against cancer. For over 65 years, the CRS has invested the funds raised
where they are deemed most useful, i.e., in the exclusive funding of cancer research.
Events that make all the difference
Fundraising activities are an invaluable source of support for the Cancer Research Society, from
both a financial standpoint and a human perspective. In 2009-2010, thanks to the involvement
of hundreds of volunteers, nearly 30 fundraising events were held across Canada, enabling us to
raise considerable funds in support of cancer research.
A look at some of our events in 2009-2010
Golf tournament presented by Uniprix
On August 26, 2010, 144 golfers gathered at the Elm Ridge Golf
Club on Île Bizard to take part in the CRS’ 17th Annual Golf
Classic. Presided by Honorary Chairman François Castonguay,
Uniprix President, the event raised a net amount of $147,724 for
cancer research.
From left to right: Domenic Pilla, François Castonguay, Mario Chevrette
and Andy Chabot.
Read for the Cure
Since 2006, a reading club has been organizing literary events in Toronto
and Ottawa featuring award-winning Random House Canadian authors.
In 2009, $70,000 was raised thanks to this reading club and to date, Read
for the Cure has raised a cumulative amount of more than $125,000 for
environment-cancer research. Read for the Cure is a non-profit Canadian
volunteer organization that raises money for the CRS.
Organizers of Read for the Cure.
Photograph donated by Henrietta Haniskova.
Rob Lutterman Ski for the Cure
On Saturday, March 13, 2010, the 11th edition of the Rob Lutterman
Ski for a Cure was held at Mont Sutton and raised $45,000 for
pancreatic cancer research. On July 28th, 1999, Rob Lutterman
lost his battle with pancreatic cancer at the age of 63. Shortly after,
his family and a group of friends decided to create an annual ski
day to raise money for cancer research and to commemorate Rob,
who was an avid skier. The Rob Lutterman Memorial Fund for
the CRS was created to promote and fund research into pancreatic
cancer: a first grant of $300,000 was awarded to researcher
Dr. Norman Kneteman of the University of Alberta. A second
grant for the same amount was awarded this past year to researcher
Dr. Michel L. Tremblay from McGill University in Montréal.
10
Cancer Research Society • Annual report 2009-2010
The first achievement for the CRS Challenge:
the Great Wall of China Marathon
The CRS Challenge is a program of fundraising expeditions organized
in support of cancer research. The first ever program challenge,
the Great Wall of China Marathon, took place in May 2010: this
marathon has the reputation of being one of the hardest on the planet.
Having survived a rigorous training and motivated by their cancer
heroes, our first participants Chrep Lok, Bruno Bernier and André
Buteau demonstrated their dedication to the cause by accomplishing
their goal at all costs: despite several difficulties, our three participants
realized their challenge in under 8 hours. This first activity of the CRS
Challenge program raised more than $30,000 for cancer research.
Step Up for the Cure
Step Up for the Cure is a 24-hour climbing marathon with
the objective to climb one stair for each of the estimated
11 million people who are diagnosed with cancer each year.
Every step counts, marking one additional step in the fight
against cancer. In 2009, the event took place in Montréal
on September 26 and raised $30,000. Since 2007, more
than $150,000 has been raised for the CRS thanks to Step
Up for the Cure and its prime organizer Dan Fisher.
Suits for the Cure
In July 2010, the CRS made an agreement with the Canadian clothing manufacturer for
men, S. Cohen. In collaboration with the CRS, the company has agreed to fund a cancer
research grant on breast cancer for an amount of $120,000. For each “Suit for the Cure”
sold, $20 will be invested in cancer research.
The CRS wishes to acknowledge the contribution of the
following activities’ organizers:
Activities
City
Province
2nd Annual Ponsard Reunion Hockey Game
Montréal
Québec
2009 Poker Challenge – Make a bet for life
Throughout Québec
Québec
A. L. Moore Golf Classic 2009
Barrie
Ontario
Centre 16-18 ans
Greenfield Park
Québec
Chicks With Stix
Cambridge
Ontario
Douglas Brian Shapiro Golf Tournament
Pine Hill
Québec
John Sanvido Memorial Golf Tournament
Guelph
Ontario
Lasalle Legion Cancer Reseach Fundraiser
Lasalle
Québec
Les Grandes Gueules et Richard Turcotte
Montréal
Québec
Marjolaine Bazinet Foundation BBQ
St-Hugues-de-Bagot
Québec
McGill University’s Desautels MBA 0-week Fundraiser
Montréal
Québec
Rase-o-thon Suzanne Plante
Mansonville
Québec
Soirée Pioneer Lacasse
Lacolle
Québec
Cancer Research Society • Annual report 2009-2010
11
Financial activities
In a relatively difficult context in many respects, the financial results of the Cancer Research
Society are considered very satisfactory. The overall fundraising activities witnessed a rate of
growth of some 28.2% while costs including administration charges showed a drop of 6.6%.
These results reflect a more targeted approach in our fundraising activities combined with tight
cost controls. The excess of revenues over expenses will allow the Cancer Research Society to
maintain a solid financial base to meet its research and other commitments in the future.
Financial position As at August 31, 2010
2010
General
Management Fund $
4,263,701 -
10,356,266 66,651 248,228 1,389,816 47,518 Environment- Cancer FundTM
$
661,907 -
-
-
-
-
-
Total $
4,925,608 -
10,356,266 66,651 248,228 1,389,816 47,518 1,106,848
29,605
9,685,731
61,668
146,795
211,218
40,913
Equipment and leasehold improvements
16,372,180 457,472 661,907 -
17,034,087 457,472 11,282,778 361,746
16,829,652 661,907 17,491,559 11,644,524 Liabilities Current liabilities Accounts payable and accrued liabilities
1,689,126 -
Deferred contributions
410,979 -
1,689,126 410,979 205,452
475,703
681,155
Assets Current assets Cash
Short-term investments
Marketable securities
Accrued interest
Amounts receivable
Prepaid expenses
Other assets
2009
Total
$
2,100,105 -
2,100,105 449,648 14,279,899 -
661,907 449,648 14,941,806 351,966
10,611,403
14,729,547 661,907 15,391,454 10,963,369
16,829,652 661,907 17,491,559 11,644,524 Net Assets Net assets invested in equipment
Unrestricted net assets before commitments
12
Cancer Research Society • Annual report 2009-2010
Financial activities 2009-2010
2010
General
Management Fund $
Environment- Cancer FundTM
$
Total $
Total
$
12,701,536 1,868,513 238,194 913,918 400,832 1,207,357 200 -
-
294,366 -
200,000 12,701,736 1,868,513 238,194 1,208,284 400,832 1,407,357 10,301,827
1,356,180
214,917
756,084
224,476
1,050,355
17,330,350 494,566 17,824,916 13,903,839
5,513,909 1,169,797 160,000 140,837 5,673,909 1,310,634 6,683,410
1,453,486
6,683,706 300,837 6,984,543 8,136,896
Campaign expenses 6,129,543 1,021 6,130,564 6,518,329
12,813,249 301,858 13,115,107 14,655,225
4,517,101 71,388 192,708 -
4,709,809
71,388
192,708 4,638,421 Revenues
General Management Funds and Environment-Cancer FundsTM
Donations from public Major and planned gifts Commemorative donations Fundraising projects Investment income Partnerships Expenses Programs Research grants Administration Excess (of expenses over revenues) of revenues over expenses before amortization after research grants
Amortization of equipment and of leasehold improvements
Excess (of expenses over revenues) of revenues over expenses after research grants 4,445,713 2009
(751,386)
71,683 (823,069)
Certain comparative figures have been reclassified to conform to the financial statement presentation adopted in the current year. Cancer Research Society • Annual report 2009-2010
13
Board of
Directors
scientific
partners
Mario Chevrette, President
Researcher & Professor, McGill University
Each year, the Cancer Research Society (CRS) funds educational
institutions, research centers, hospitals, foundations and alliances
through its fellowships and strategic & operational grants, in both
basic and environment-cancer research.
Annick Bergeron, Vice-President
Lawyer, Director of Legal Affairs
Université de Montréal
Micheline Bouchard, Secretary
Lawyer, Loranger, Marcoux g.p.
Nathalie Labelle, Treasurer
Partner, Chartered Accountant, KPMG
Here is the list of organizations which have benefited from CRS
funding:
British Columbia Cancer Agency, Vancouver, British Columbia
Centre de recherche de l’Hôtel-Dieu de Québec, Québec, Québec
Centre de recherche du CHUL (CHUQ), Québec, Québec
Centre de recherche du CHUM (CRCHUM), Montréal, Québec
Centre hospitalier de l’Université de Sherbrooke, Sherbrooke, Québec
Michel G. Bouchard, Director
Partner, Cheverny Capital
Centre hospitalier de l’Université Laval (CHUL), Québec, Québec
Marie-Kym Brisson, Director
Vice-President, Public Affairs and
Communications, Génome Québec
Hôpital Maisonneuve-Rosemont, Montréal, Québec
François Des Rochers, Director
Director, Market development,
Information Systems, Alogient
Lucie Jeannotte, Director
Professor, Centre de recherche en cancérologie
de l’Université Laval
CHU Sainte-Justine Research Center, Montréal, Québec
Hôpital Notre-Dame du CHUM, Montréal, Québec
Hôtel-Dieu de Montréal, Montréal, Québec
Hôtel-Dieu de Québec, Québec, Québec
Institut de recherches cliniques de Montréal, Montréal, Québec
Jack Bell Research Centre, Vancouver, British Columbia
McGill University Health Centre, Montréal, Québec
McGill University, Montréal, Québec
McMaster University, Hamilton, Ontario
Memorial University of Newfoundland, St. John’s, Newfoundland
Heidi Lange, Director
President, Lange Consulting Inc.
Montreal General Hospital, Montréal, Québec
Gail C. Snyder, Director
Communications and Marketing Consultant
Ottawa Health Research Institute, Ottawa, Ontario
Denis Soulières, Director
Physician, Hôpital Notre-Dame
Richard M. Wise, Director
Managing Partner, Wise, Blackman LLP
Mount Sinai Hospital, Toronto, Ontario
Queen’s University, Kingston, Ontario
Sunnybrook Research Institute, Toronto, Ontario
The Hospital for Sick Children, Toronto, Ontario
Université de Montréal, Montréal, Québec
Université de Sherbrooke, Sherbrooke, Québec
Université du Québec à Montréal (UQAM), Montréal, Québec
University Health Network, Toronto, Ontario
University of Alberta, Calgary, Alberta
University of British Columbia, Vancouver, British Columbia
University of Calgary, Calgary, Alberta
University of Guelph, Guelph, Ontario
University of Manitoba, Winnipeg, Manitoba
University of Ottawa, Ottawa, Ontario
University of Toronto, Toronto, Ontario
University of Victoria, Victoria, British Columbia
University of Western Ontario, London, Ontario
University of Windsor, Windsor, Ontario
Vancouver Hospital & Health Sciences Centre,
Vancouver, British Columbia
14
Cancer Research Society • Annual report 2009-2010
donors
®
The Cancer Research Society (CRS) truly appreciates the support obtained from the businesses, foundations, employee
committees and other organizations involved in the fight against cancer. We would like to thank the 230,000 donors
who enable the CRS to support cancer research.
$100,000 and more
BMO MasterCard
Fonds de la recherche
en santé du Québec
Guzzo Cinemas
Rio Tinto Alcan
From $25,000 to $99,999
Anonymous
Bergeron-Jetté Foundation
CN Employees’ and
Pensioners’ Community
Fund
McKesson Canada
Read for the Cure
Rita Steinberg Goldfarb
Foundation
Rob Lutterman Ski for
a Cure
Step Up for the Cure
Uniprix Group
From $10,000 to $24,999
2009 Poker Challenge: Make
a Bet for Life
Andy Chabot Fund
CanadaHelps.org
Consortia
Création Paul H.
John Sanvido Memorial Golf
Tournament
Marjolaine-Bazinet
Foundation BBQ
Pepsi
Strategic Charitable Giving
Foundation
The Jewish Community
Foundation of Montreal
From $5,000 to $9,999
Apotex
Bell Canada
BMO Employee Charitable
Foundation
Brickmill Marketing Services
CGI
Chicks with Stix
Dunton Rainville
EssOR InsuranceInvestment-Counselling
Freedom 55 Financial
Imperial Popcorn
Investissement
Guy Locas inc.
Investissement Québec
Laboratory Du-Var Inc.
Le Château
Ogilvy Renault
ratiopharm
Sandoz Canada
SMi
Teva Canada
The Charles Norcliffe Baker
& Thelma Scott Baker
Foundation
The Great-West Life
Assurance Company
Vortex Solution
Wellington Laboratories Inc.
Yvon Michel Group
From $1,000 to $4,999
152245 Canada inc.
171909 Canada inc.
2nd Annual Ponsard Reunion
Hockey Game
4165373 Canada inc.
91304717 Québec inc.
A. & D. Prévost Inc.
A. L. Moore Golf Classic
AECOM Tecsult
Alliance Atlantis Vivafilm
Aqua Spa Lyne Giroux inc.
Artcom
Association Sociale et
Culturelle de Matrice
Associazione Santa Fortunata
ATCO Gas Employee
Community Service Fund
AutoSkin
Axor
Beauchemin Communication
Marketing inc.
Blain Joyal Charbonneau
Compatables agrées
s.e.n.c.r.l.
BMO Nesbitt Burns
BPR
Bristol-Myers Squibb Canada
Canada Post
Canaropa
Cargill Limited
Carlyle & Associates
Carpian Consultants Inc.
Centre 16-18 ans
Centre Dentaire Carré
Léonard Labelle et Associés
Chanel Inc.
CIBC Wood Gundy
Club Optimiste Melocheville
Congrégation des Filles de la
Providence
Crescent Commercial
Corporation
Cucciniello Calandriello
Czybo Investments Inc.
Dayus Register & Grille Inc.
Déneigement S.R.
Desautels MBA 0-Week
Fundraiser
Desdowd Inc.
Desjardins Card Services
Desjardins Centre Financier
aux Entreprises de l’Est de
Montréal
Desjardins General Insurance
Dessau inc.
Dic Ann’s
Dic Ann’s Foundation
Dorel Industries Inc.
Douglas Shapiro Memorial
Fund
Dr. Erwin Chao Medical
Prof. Corp.
EnCana Cares Foundation
Equinox Industries
Euro-Pharm International
Canada Inc.
Fasken Martineau
Dumoulin LLP
Ferrari Québec
Fidelity Investments
Canada Ltd.
Fiesta Tents Ltd.
Film Service Supérieur inc.
Fondation Denise et Robert
Gibelleau
Fondation Hormisdas Pilon
Fondation Pain & Espoir
Fondation Sibylla Hesse
Garnier Construction Ltd.
Gestion André Waechter
Gestion Dumel inc.
Gestion SoplaJoey inc.
GML Mechanical Ltd.
Griva-Pete Holdings Inc.
Groupe Enxium inc.
Groupe IBI/DAA
Groupe Parim inc.
Groupe Ressources Des
Moulins
Harvest Foundation
HBOC Society of Alberta
Hershey Canada Inc.
Hoco Ltd.
Hydro-Québec
IMS Health
Industrial Alliance Insurance
and Financial Services Inc.
Interpaving Limited
Jamp Pharma Corporation
Janssen-Ortho Inc.
Jean-Paul Beaudry Ltée
John Warren Imports Inc.
Kanner Westmount Inc.
Kaufmann De Suisse Jewelers
KPMG LLP
La Capitale Cosmo Roselli
La Cie d’Éclairage Union
La Sirène De La Mer
Restaurant Poissonnerie
Lasalle Legion Cancer
Reseach Fundraiser
Lavoie & Masciotra
Les Centres D’Achats
Beauward Ltée
Les Filles de Jésus
Les Films Seville / EOne
entertainment
Leslie & Irene Dubé
Foundation
Les Pavages Tallarita
Canada inc.
Les Pavés Futurs
Les Productions Feeling inc.
Liberty Sites Ltd.
Logistik Unicorp Inc.
Londono Realty Group
Lorenco Steel Inc.
Loto-Québec
Louis Vuitton
Marchand Melançon Forget
Marché Central (Bentall LP)
Mécanique Ron Toohey inc.
Merck Frosst Canada Ltd.
Mersynergy Charitable
Foundation
Modico Canada
MPA Gestion Financière inc.
National Bank Financial
Group
Nightclub 54
Parasuco Jeans
Pharmapar
Pharmascience
PitneyBowes Canada Ltd.
PricewaterhouseCoopers
Primolio Sales Inc.
Prisma Construction
Pro Locksmiths Ltd.
Proprio Direct
Province of Manitoba All
Charities Campaign
Qualité Pro Conseils inc.
Quebec’s Casinos
Quincaillerie Demers inc.
Rase-o-thon Suzanne Plante
RBC Foundation
RCR International inc.
Richelieu Hosiery Intl Inc.
Robic LLP
Rubino Shoes
Saputo inc.
Schwartz Levitsky
Feldman LLP
Scotiabank
Signature Bachand
S.M. Group International
Sœurs des Saints Noms de
Jésus et de Marie
Soirée d’appréciation Pioneer
Lacasse
Standard Life Assurance
Company of Canada
Starnino Mostovac LLP
St-Lambert Games
TD Waterhouse-Private
Giving Foundation
Telus
The CSL Group Inc.
The Evelyn Steinberg
Alexander Family
Foundation
The John Brouwer
Foundation
The Reformed Mennonite
Church
Tribute Magazine
Universal Studios
Canada Inc.
Université de Montréal
Vasco
Via Rail Canada Inc.
W D Latimer Co. Ltd.
Westwood Mechanical Inc.
Wilson Machine
Zone 3 XXVII Inc
Cancer Research Society • Annual report 2009-2010
15
Published by
Communications and Marketing
Cancer Research Society
625 President-Kennedy Avenue, Suite 402
Montréal, QC H3A 3S5
Telephone: 514 861-9227
Toll-free: 1 888 766-2262
www.CancerResearchSociety.ca
Graphic design: Prétexte Communications
Print production: Au Point-Reprotech
ISSN 1920-9029
Legal deposit – Bibliothèque nationale du Québec, 2010
Legal deposit – Library and Archives Canada, 2010
Printed in Canada
C